New positive ivermectin evidence
A Pilot, Randomised, Placebo-Controlled, Double-Blind Trial of a Single Oral Dose of Ivermectin for Post-Exposure Prophylaxis of SARS-CoV-2https://www.mdpi.com/1999-4923/17/9/1205
People who took one small oral dose of ivermectin after exposure,
took longer to test positive and had more time alive and free of symptoms.
Multiple reports from in vitro infectious models document Ivermectin’s antiviral properties
https://pmc.ncbi.nlm.nih.gov/articles/PMC7564151/pdf/cells-09-02100.pdf
Ivermectin has broad-spectrum antiviral activity.
Randomised, double-blind, placebo-controlled
Single oral dose of Ivermectin as prophylaxis for SARS-CoV-2
Trial to evaluate the effectiveness of a single oral low dose of Ivermectin
Ability to prevent SARS-CoV-2 infection?
Ability to reduce symptoms if infection did occur?
Methods
Asymptomatic community-dwelling adults
Enrolled within 72 h of close contact with a case of SARS-CoV-2.
Single oral 200 µg/kg dose of Ivermectin or placebo.
65Kg woman given 13mg
80Kg man given 16mg
The primary outcome
Conversion to a positive PCR or RAT test within 14 days of close contact.
Secondary outcomes
(for those who tested positive)
Days alive free of symptoms in the 14 and 28 days following ivermectin
Days from close contact until a positive PCR or RAT
Results
N = 536 (86 met inclusion criteria and were randomised)
68 adhered and were included in the analysis.
Ivermectin arm
11/36 tested positive
Placebo arm
11/32 tested positive
So, ivermectin did not prevent people testing positive
Days from close contact until a positive PCR or RAT
Increased by 2.3 days in ivermectin group.
P = 0.033
So, ivermectin lengthened the incubation period
Viral load needed to precipitate clinical disease took longer to develop – indicating an antiviral effect.
Infection may have been prevented from primary contact, - indicating an antiviral effect.
Days alive free of symptoms
Increased by 2.5 days in ivermectin group.
P = 0.036
So ivermectin delayed onset of symptoms in people who tested positive
(Longer asymptomatic period)
Controlling included
Age, prior SARS-CoV-2 infection, body mass index, hypertension, lung disease
Conclusions
We did not demonstrate that a single oral low dose of Ivermectin administered to asymptomatic adults within 72 h of close contact with a case of
SARS-CoV-2 prevents conversion to a positive PCR or RAT.
(may have done with a larger sample size)
Amongst those who did convert to a positive PCR or RAT
Ivermectin significantly lengthened the time from close contact to conversion
Ivermectin increased the number of days alive free of symptoms
More details
Initiation of this trial in late 2021
Discovery in 1975
Massively used around the world
Nobel Prize in 2015
Very low incidence of serious adverse side effects
No instance of resistance reported in over 25 years.
Ivermectin can bind to and inhibit the nuclear transport roles of the host importin α (IMPα) protein,
which is known to mediate the nuclear import of various viral proteins and key host factors.
Other quite distinct antiviral actions of Ivermectin have been proposed
High (therapeutic) concentrations collect in the lungs, stable for more than 30 days in cattle
Trial was based on the strong clinical retrospective association of statistically significantly lower mortality in patients who received oral Ivermectin (200 μg/kg) compared with usual care
https://www.sciencedirect.com/science/article/pii/S0012369220348984
Ivermectin patients 15% mortality
Controls, 25.2% mortality
In subjects with severe pulmonary disease
Ivermectin patients, mortality 38.8%
Controls, 80.7% mortality Receive SMS online on sms24.me
TubeReader video aggregator is a website that collects and organizes online videos from the YouTube source. Video aggregation is done for different purposes, and TubeReader take different approaches to achieve their purpose.
Our try to collect videos of high quality or interest for visitors to view; the collection may be made by editors or may be based on community votes.
Another method is to base the collection on those videos most viewed, either at the aggregator site or at various popular video hosting sites.
TubeReader site exists to allow users to collect their own sets of videos, for personal use as well as for browsing and viewing by others; TubeReader can develop online communities around video sharing.
Our site allow users to create a personalized video playlist, for personal use as well as for browsing and viewing by others.
@YouTubeReaderBot allows you to subscribe to Youtube channels.
By using @YouTubeReaderBot Bot you agree with YouTube Terms of Service.
Use the @YouTubeReaderBot telegram bot to be the first to be notified when new videos are released on your favorite channels.
Look for new videos or channels and share them with your friends.
You can start using our bot from this video, subscribe now to New positive ivermectin evidence
What is YouTube?
YouTube is a free video sharing website that makes it easy to watch online videos. You can even create and upload your own videos to share with others. Originally created in 2005, YouTube is now one of the most popular sites on the Web, with visitors watching around 6 billion hours of video every month.
